# A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia

> **NCT03174886** · PHASE1 · UNKNOWN · sponsor: **Axon Neuroscience SE** · enrollment: 33 (actual)

## Conditions studied

- Primary Progressive Nonfluent Aphasia

## Interventions

- **DRUG:** AADvac1 40 µg
- **DRUG:** AADvac1 160 µg

## Key facts

- **NCT ID:** NCT03174886
- **Lead sponsor:** Axon Neuroscience SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-31
- **Primary completion:** 2020-11
- **Final completion:** 2020-11
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03174886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03174886, "A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03174886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*